scholarly journals Factors Associated with Low Bone Density in Opioid Substitution Therapy Patients: A Systematic Review

2021 ◽  
Vol 18 (2) ◽  
pp. 575-581
Author(s):  
Fitri Fareez Ramli ◽  
Syed Alhafiz Syed Hashim ◽  
Nadia Mohd Effendy
Keyword(s):  
Systematic Review ◽  
Bone Density ◽  
Substitution Therapy ◽  
Opioid Substitution Therapy ◽  
Factors Associated ◽  
Low Bone Density ◽  
Opioid Substitution

scholarly journals Impact of Opioid Substitution Therapy on Antiretroviral Therapy Outcomes: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 63 (8) ◽  
pp. 1094-1104 ◽  
Author(s):  
Andrea J. Low ◽  
Gitau Mburu ◽  
Nicky J. Welton ◽  
Margaret T. May ◽  
Charlotte F. Davies ◽  
...  
Keyword(s):  
Systematic Review ◽  
Antiretroviral Therapy ◽  
Meta Analysis ◽  
Therapy Outcomes ◽  
Substitution Therapy ◽  
Opioid Substitution Therapy ◽  
Opioid Substitution

scholarly journals Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials

2018 ◽  
Vol 5 (11) ◽  
Author(s):  
Jason Grebely ◽  
Massimo Puoti ◽  
Heiner Wedemeyer ◽  
Curtis Cooper ◽  
Mark S Sulkowski ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Hepatitis C ◽  
Treatment Adherence ◽  
Efficacy And Safety ◽  
Substitution Therapy ◽  
Hcv Treatment ◽  
Opioid Substitution Therapy ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Opioid Substitution

Abstract Background We evaluated the impact of opioid substitution therapy (OST) on the completion, adherence, efficacy, and safety of the 3-direct-acting antiviral regimen of ombitasvir, paritaprevir (identified by AbbVie and Enanta) co-dosed with ritonavir, and dasabuvir ± ribavirin among patients infected with hepatitis C virus (HCV) genotype (GT) 1, with or without compensated cirrhosis. Methods Data were pooled from GT1-infected patients enrolled in 12 phase II/III/IIIb clinical trials and categorized by use of OST. Patients with ongoing drug use were excluded. HCV treatment completion, treatment adherence (≥90%), sustained virologic response at post-treatment week 12 (SVR12), and adverse events were assessed. Results Of 4747 patients, 3% (n = 149) received OST. Among patients receiving OST vs those not receiving OST, 82% (n = 122) vs 52% (n = 2409) had GT1a infection; 76% (n = 113) vs 61% (n = 2792) were treatment naïve; and 17% (n = 25) vs 18% (n = 830) had cirrhosis, respectively. The proportion of patients completing HCV treatment did not differ between those receiving and not receiving OST (97% [n = 144] vs 98% [n = 4510], respectively), whereas adherence to treatment was reduced in patients receiving vs those not receiving OST (88% [n = 105] vs 97% [n = 4057], respectively). SVR12 was similar between patients receiving and not receiving OST (94% [n = 140] vs 96% [n = 4405], respectively; P = .273). Treatment was well tolerated. Conclusions Although treatment adherence was lower in patients receiving OST vs those not receiving OST, treatment completion and SVR12 were similar between groups. These data support the use of direct-acting antiviral therapies in patients receiving OST.

Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine

2017 ◽  
Vol 31 (5) ◽  
pp. 574-579 ◽  
Author(s):  
Melissa Yéléhé-Okouma ◽  
Hervé Martini ◽  
Jérémie Lemarié ◽  
Pierre Labroca ◽  
Nadine Petitpain ◽  
...  
Keyword(s):  
Case Series ◽  
Substitution Therapy ◽  
Opioid Substitution Therapy ◽  
Atypical Case ◽  
Opioid Substitution
Sign in / Sign up

Export Citation Format

Share Document